Placebo | ABT-126 25 mg | ABT-126 50 mg | ABT-126 75 mg | Donepezil 10 mg | All subjects | |
---|---|---|---|---|---|---|
Number of subjects | 104 | 77 | 107 | 73 | 75 | 436 |
Age (years), mean ± SD | 73.2 ± 7.39 | 73.0 ± 7.62 | 73.9 ± 8.26 | 76.2 ± 8.14 | 75.1 ± 7.75 | 74.2 ± 7.89 |
Age < 75 years, n (%) | 59 (56.7) | 37 (48.1) | 50 (46.7) | 30 (41.1) | 30 (40.0) | 206 (47.2) |
Age ≥ 75 years, n (%) | 45 (43.3) | 40 (51.9) | 57 (53.3) | 43 (58.9) | 45 (60.0) | 230 (52.8) |
Female, n (%) | 65 (62.5) | 40 (51.9) | 68 (63.6) | 52 (71.2) | 40 (53.3) | 265 (60.8) |
Male, n (%) | 39 (37.5) | 37 (48.1) | 39 (36.4) | 21 (28.8) | 35 (46.7) | 171 (39.2) |
White, n (%) | 91 (87.5) | 75 (97.4) | 96 (89.7) | 64 (87.7) | 70 (93.3) | 396 (90.8) |
BMI (kg/m2), mean ± SD | 26.2 ± 3.88 | 27.1 ± 4.91 | 26.0 ± 4.98 | 25.5 ± 4.62 | 25.0 ± 4.27 | 26.0 ± 4.57 |
Age at AD symptom onset (years), mean ± SD | 69.6 ± 7.66 | 69.2 ± 8.51 | 70.2 ± 8.67 | 72.3 ± 7.97 | 71.2 ± 8.24 | 70.4 ± 8.25 |
Years since AD symptom onset,a mean ± SD | 3.7 ± 2.61 | 4.1 ± 2.96 | 3.9 ± 3.11 | 4.2 ± 2.67 | 4.2 ± 2.45 | 4.0 ± 2.78 |
Age at AD diagnosis (years), mean ± SD | 72.1 ± 7.60 | 71.5 ± 8.10 | 72.5 ± 8.64 | 74.8 ± 8.30 | 73.6 ± 7.91 | 72.8 ± 8.16 |
Years since AD diagnosis, mean ± SD | 1.1 ± 1.79 | 1.5 ± 1.91 | 1.4 ± 2.37 | 1.5 ± 1.96 | 1.6 ± 1.92 | 1.4 ± 2.02 |
Family history of AD, n (%) | 22 (21.2) | 20 (26.0) | 23 (21.5) | 6 (8.2 %) | 10 (13.3) | 81 (18.6) |
ADAS-Cog (11-item),b mean ± SD | 26.1 ± 10.98 | 24.6 ± 11.45 | 25.6 ± 11.32 | 27.2 ± 9.81 | 27.9 ± 12.08 | 26.2 ± 11.16 |
MMSE score, mean ± SD | 19.1 ± 4.00 | 20.0 ± 4.09 | 18.6 ± 4.03 | 18.6 ± 3.87 | 18.4 ± 4.42 | 18.9 ± 4.09 |
Number of subjects | 92 | 66 | 97 | 63 | 64 | 382 |
APOE ε4 positive, n (%) | 37 (40.2) | 34 (51.5) | 48 (49.5) | 27 (42.9) | 32 (50.0) | 178 (46.6) |